Danish biotech prices in nervous market

Genmab, the Danish biotech company, on Wednesday priced its shares just above the bottom of the indicative range, signalling a possible slump in investor appetite for biotech stocks.

Genmab, which is seeking a dual listing on its home market, the Copenhagen Stock Exchange, as well Frankfurt's Neuer Markt for high-growth companies, priced its shares at €34.89 ($30.32), almost touching the bottom of the €34 to €40 indicated range.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump